Table 1.
Study characteristics
| Ref. | Years data collected | Country | Type of study | Total n | % of group receiving chemo | Predominant chemotherapy regime | Targeted agent use |
| 2 arms: PTR vs PC | (PTR n/PC n) | (PTR/PC) | |||||
| Yun et al[18] (2014) | 2000-2008 | South Korea | Retrospective, propensity-score matched cohort, single centre | 416 (218/198) | 66/100 | Doublet | ND |
| Matsumoto et al[19] (2014) | 2005-2011 | Japan | Retrospective, single centre | 88 (41/47) | 85/100 | Doublet | Approx 50% received targeted agent |
| Ahmed et al[42] (2014) Subgroup | 1992-2005 | Canada | Retrospective, multicentre | 834 | 100/100 | ND | < 2% |
| Cetin et al[22] (2013) | 2006-2010 | Turkey | Retrospective, multi centre | 99 (53/46) | 100/100 | Doublet | 100% received bevacizumab |
| Boselli et al[15] (2013) | 2010-2011 | Italy | Retrospective, single centre | 48 (17/31) | 65/100 | Doublet | > 50% received bevacizumab 1st line |
| Seo et al[20] (2010) | 2001-2008 | South Korea | Retrospective, single centre | 227 (144/83) | 100/100 | Doublet | 5%-10% received bevacizumab; 5%-10% received EGFR monoclonal antibody |
| Galizia et al[25] (2008) | 1995-2005 | Italy | Retrospective, single centre | 65 (42/23) | 100/100 | Singlet | Nil |
| Benoist et al[26] (2005) | 1997-2002 | France | Retrospective, case matched, single centre | 59 (32/27) | 94/100 | Singlet | Nil |
| Michel et al[21] (2004) | 1996-1999 | France | Retrospective, single centre | 54 (31/23) | 97/100 | Doublet | Nil |
| Ruo et al[43] (2003) | 1996-1999 | United States | Retrospective, single centre | 230 (127/103) | ND/83 | Singlet | Nil |
| Scoggins et al[44] (1999) | 1985-1997 | United States | Retrospective, single centre | 89 (66/23) | ND/100 | Singlet | Nil |
| Single arm: Primary chemotherapy | n | % group receiving chemo | |||||
| Yun et al[23] (2014) | 2000-2011 | South Korea | Retrospective, single centre | 259 | 100 | Doublet | ND |
| McCahill et al[16] (2012) | 2006-2009 | United States | Prospective Phase 2 | 86 | 100 | Doublet | 100% received bevacizumab |
| Clements et al[45] (2009) | 2003-2006 | United Kingdom | Retrospective, single centre | 37 | 92 | Doublet | ND |
| Bajwa et al[27] (2009) | 1999-2005 | United Kingdom | Retrospective, single centre | 67 | 100 | Doublet | ND |
| Poultsides et al[24] (2009) | 2000-2006 | United States | Retrospective, single centre | 233 | 100 | Doublet | 48% received bevacizumab 1st line |
| Muratore et al[46] (2007) | 2000-2004 | Italy | Prospective, single centre | 35 | 100 | Doublet | Nil |
| Sarela et al[47] (2001) | 1997-2000 | United Kingdom | Retrospective and prospective, single centre | 24 | 87 | Singlet | Nil |
| Single arm: Primary tumour resection | n | % group receiving chemo | |||||
| Maeda et al[28] (2013) | 2001-2009 | Japan | Retrospective, single centre | 94 | 85 | Doublet | 33% received targeted agent |
| Matsuda et al[17] (2012) | 1998-2007 | Japan | Retrospective, single centre | 40 | 74 | Doublet | ND |
PTR: Primary tumour resection; PC: Primary chemotherapy; ND: Not documented.